Aim: Comparing the effect of Faster Aspart insulin (Fiasp®) with previous insulin analogues (aspart, lispro) in type I diabetic patients with sensor-augmented pump therapy.
Methods: Patients with Minimed Paradigm® insulin pumps, Enlite® sensors and Guardian® software (able to automatically stop the pump infusion to prevent hypoglycemia) were switched from previous insulin to Faster Aspart. Data from the previous 3 months and 3 months afterwards were obtained from the Guardian® software and compared by Students paired t-test. Satisfaction data were obtained by analogic scales. Data are given as mean±S.D.
Results: Sixteen patients (age 23±6.8 years, 69% female) were switched to Faster Aspart from lispro (25%) and aspart (75%). Their glycemic variability coefficient (100 x mean glucose/S.D.) was significantly reduced from 41.3±9.2% to 34.2+8.9% (P=0.0342). Time on glucose <70 mg/dl was significantly reduced from 3.8±1.3% to 2.9+0.9% (P=0.0301), Time on glucose >180 mg/dL was reduced from 6.7±1.9% to 5.5+1.8% (P=0.0766), HbA1C decreased from 7.3±0.9% to 6.9+0.8% (P=0.1940). On a 010 visual analogical scale, patient satisfaction was significantly increased from 6.3±1.8 to 7.8+1.4% (P=0.0133). No unexpected adverse effects were reported.
Conclusions: In this open, uncontrolled study, switching from previous insulin analogues to Faster Aspart was well-tolerated and significantly reduced glycemic variability and time on hypoglycemia; patient satisfaction was significantly increased, and trends for lower time on hyperglycemia and lower HbA1C were found. We conclude that Faster Aspart is an advantageous alternative to the classic fast-acting insulin analogues for patients on sensor-augmented insulin pump therapy.
18 May 2019 - 21 May 2019